Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association’s 2026 Scientific Sessions
Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions. The presentation will be delivered by W. Timothy Garvey, MD, a globally recognized authority in obesity and metabolic medicine and a scientific advisor...
Free Tickets Open for 2026 Medtec
SHANGHAI, April 2, 2026 /PRNewswire/ -- Free tickets for 2026 Medtec open on April 1, 2026. Visitors who complete registration before August 31 can enter free of charge. As Asia's Leading Medical Device Supply Chain Expo — From R&D to Commercial Manufacturing, 2026 Medtec will be held from September 1–3, 2026, at the Shanghai New International Expo Centre (SNIEC), Pudong,...
CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala
SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. The evening, co-hosted by Founding Platinum Sponsor Wilson Sonsini and the BayHelix Group, recognized outstanding achievements in healthcare investment, financing, and deal-making over the...
Telix Appoints David Gill as Non-Executive Director
MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 2026. Mr. Gill is expected to be appointed as...
NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
Pressing issues in oncology, including rising cancer incidences in younger people, plus global opportunities for improving outcomes, were presented alongside cutting-edge research and clinical guidelines updates, during yearly event hosted by the National Comprehensive Cancer Network. ORLANDO, Fla., April 2, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a non-profit alliance of leading...
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
SUZHOU, China, April 1, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with Docetaxel for Injection (Albumin-bound) (HB1801), has met the pre-specified primary endpoint...
Smartee Introduces Material and Trimline Selection Features to Enhance Aligner Customization
SHANGHAI, April 1, 2026 /PRNewswire/ -- Smartee Denti-Technology today announced the addition of Material Choice and Trimline Selection features to its digital case management system SmarteeCheck. Available immediately at the case approval stage, these updates provide clinicians with greater flexibility to further customize treatment plans based on personal preferences and dental condition of individual patients. Material Choice: Balancing Precision...
Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
- Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases - - BBT001 achieved rapid, deep, and sustained effects on key biomarkers of interest in AD for at least 12 weeks,...
Prudential Health Summit: Improving Care for Every Patient brings healthcare leaders together to support patients in Hong Kong and the Greater Bay Area
HONG KONG, April 1, 2026 /PRNewswire/ -- Prudential Hong Kong Limited ("Prudential") hosted the Prudential Health Summit: Improving care for every patient ("the Summit") on 27 March, 2026. The Summit brought together healthcare experts, providers, academia, industry partners and patient groups from Hong Kong and the Greater Bay Area to exchange practical ideas for...
Sino Biological ProPure™ Endotoxin-Free Proteins: The “Invisible Guardian” of Biopharmaceuticals
HOUSTON, April 1, 2026 /PRNewswire/ -- After months of meticulous work, your cells suddenly behave unpredictably, or your mouse models develop fever and systemic inflammation during critical studies. The hidden culprit may be endotoxin, the lipopolysaccharide (LPS) from gram-negative bacteria. Even trace amounts can compromise biological products, causing adverse reactions and regulatory headaches. Endotoxin-free recombinant proteins are the...
